StockNews.com began coverage on shares of MEI Pharma (NASDAQ:MEIP – Free Report) in a research note issued to investors on Friday. The brokerage issued a buy rating on the stock. Several other equities research analysts also recently weighed in on the company. Brookline Capital Management downgraded MEI Pharma from a “strong-buy” rating to a “hold” […]